REGENXBIO

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell REGENXBIO and other ETFs, options, and stocks.

About RGNX

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381.

CEO

Kenneth T. Mills

CEOKenneth T. Mills

Employees

344

Employees344

Headquarters

Rockville, Maryland

HeadquartersRockville, Maryland

Founded

2008

Founded2008

Employees

344

Employees344

RGNX Key Statistics

Market cap

831.41M

Market cap831.41M

Price-Earnings ratio

-2.80

Price-Earnings ratio-2.80

Dividend yield

—

Dividend yield—

Average volume

369.06K

Average volume369.06K

High today

$17.15

High today$17.15

Low today

$16.31

Low today$16.31

Open price

$16.93

Open price$16.93

Volume

402.09K

Volume402.09K

52 Week high

$28.80

52 Week high$28.80

52 Week low

$11.83

52 Week low$11.83

Analyst ratings

92%

of 12 ratings

Buy

91.7%

Hold

8.3%

Sell